Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PARP1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PARP1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PARP1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PARP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PARP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PARP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PARP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PARP1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PARP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001003824 | Breast | DCIS | response to metal ion | 65/1390 | 373/18723 | 8.03e-11 | 9.88e-09 | 65 |
GO:000675423 | Breast | DCIS | ATP biosynthetic process | 21/1390 | 57/18723 | 2.64e-10 | 3.11e-08 | 21 |
GO:000920123 | Breast | DCIS | ribonucleoside triphosphate biosynthetic process | 24/1390 | 74/18723 | 3.04e-10 | 3.44e-08 | 24 |
GO:000914423 | Breast | DCIS | purine nucleoside triphosphate metabolic process | 26/1390 | 88/18723 | 5.62e-10 | 5.89e-08 | 26 |
GO:000920523 | Breast | DCIS | purine ribonucleoside triphosphate metabolic process | 25/1390 | 82/18723 | 5.75e-10 | 5.91e-08 | 25 |
GO:000914223 | Breast | DCIS | nucleoside triphosphate biosynthetic process | 25/1390 | 85/18723 | 1.33e-09 | 1.33e-07 | 25 |
GO:000919923 | Breast | DCIS | ribonucleoside triphosphate metabolic process | 25/1390 | 89/18723 | 3.84e-09 | 3.24e-07 | 25 |
GO:000914123 | Breast | DCIS | nucleoside triphosphate metabolic process | 28/1390 | 112/18723 | 8.02e-09 | 6.30e-07 | 28 |
GO:006219724 | Breast | DCIS | cellular response to chemical stress | 56/1390 | 337/18723 | 9.64e-09 | 7.38e-07 | 56 |
GO:003196022 | Breast | DCIS | response to corticosteroid | 35/1390 | 167/18723 | 1.69e-08 | 1.18e-06 | 35 |
GO:007099724 | Breast | DCIS | neuron death | 57/1390 | 361/18723 | 4.56e-08 | 2.84e-06 | 57 |
GO:000915223 | Breast | DCIS | purine ribonucleotide biosynthetic process | 34/1390 | 169/18723 | 7.77e-08 | 4.47e-06 | 34 |
GO:005140222 | Breast | DCIS | neuron apoptotic process | 43/1390 | 246/18723 | 1.16e-07 | 6.13e-06 | 43 |
GO:004639022 | Breast | DCIS | ribose phosphate biosynthetic process | 36/1390 | 190/18723 | 1.59e-07 | 8.19e-06 | 36 |
GO:000926022 | Breast | DCIS | ribonucleotide biosynthetic process | 35/1390 | 182/18723 | 1.62e-07 | 8.24e-06 | 35 |
GO:005109823 | Breast | DCIS | regulation of binding | 55/1390 | 363/18723 | 3.14e-07 | 1.48e-05 | 55 |
GO:005110123 | Breast | DCIS | regulation of DNA binding | 26/1390 | 118/18723 | 4.09e-07 | 1.87e-05 | 26 |
GO:001969324 | Breast | DCIS | ribose phosphate metabolic process | 58/1390 | 396/18723 | 4.80e-07 | 2.11e-05 | 58 |
GO:000915024 | Breast | DCIS | purine ribonucleotide metabolic process | 55/1390 | 368/18723 | 4.92e-07 | 2.14e-05 | 55 |
GO:004325424 | Breast | DCIS | regulation of protein-containing complex assembly | 61/1390 | 428/18723 | 6.32e-07 | 2.71e-05 | 61 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARP1 | SNV | Missense_Mutation | rs79529505 | c.1223N>G | p.Val408Gly | p.V408G | P09874 | protein_coding | deleterious(0) | benign(0.367) | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PARP1 | SNV | Missense_Mutation | rs79529505 | c.1223N>G | p.Val408Gly | p.V408G | P09874 | protein_coding | deleterious(0) | benign(0.367) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
PARP1 | SNV | Missense_Mutation | rs377195931 | c.919N>A | p.Asp307Asn | p.D307N | P09874 | protein_coding | tolerated(0.23) | benign(0.189) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PARP1 | SNV | Missense_Mutation | rs377195931 | c.919G>A | p.Asp307Asn | p.D307N | P09874 | protein_coding | tolerated(0.23) | benign(0.189) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
PARP1 | SNV | Missense_Mutation | rs79529505 | c.1223N>G | p.Val408Gly | p.V408G | P09874 | protein_coding | deleterious(0) | benign(0.367) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PARP1 | SNV | Missense_Mutation | | c.2032N>C | p.Asp678His | p.D678H | P09874 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
PARP1 | SNV | Missense_Mutation | | c.2524G>A | p.Glu842Lys | p.E842K | P09874 | protein_coding | tolerated(0.18) | benign(0.026) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PARP1 | SNV | Missense_Mutation | novel | c.2971G>C | p.Val991Leu | p.V991L | P09874 | protein_coding | deleterious(0.01) | possibly_damaging(0.796) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP1 | SNV | Missense_Mutation | novel | c.1102A>C | p.Thr368Pro | p.T368P | P09874 | protein_coding | tolerated(0.29) | benign(0.079) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP1 | SNV | Missense_Mutation | | c.268N>A | p.Glu90Lys | p.E90K | P09874 | protein_coding | tolerated(0.09) | possibly_damaging(0.566) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Quinazolinedione derivative 2 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | 223366069 | RUCAPARIB | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | CHEMBL1094636 | NIRAPARIB | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | 4-Carboxamido-isoindolinone derivative 2 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | CC-486 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 5 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | OLAPARIB | OLAPARIB | 28454547,25144364,26650448 |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | 4-Carboxamido-isoindolinone derivative 3 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Phthalazine ketone derivative 3 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | RUCAPARIB | RUCAPARIB | |